These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 35305453)

  • 1. Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients.
    van Mackelenbergh MT; Seither F; Möbus V; O'Shaughnessy J; Martin M; Joensuu H; Untch M; Nitz U; Steger GG; Miralles JJ; Barrios CH; Toi M; Bear HD; Muss H; Reimer T; Nekljudova V; Loibl S
    Eur J Cancer; 2022 May; 166():185-201. PubMed ID: 35305453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.
    Hoon SN; Lau PK; White AM; Bulsara MK; Banks PD; Redfern AD
    Cochrane Database Syst Rev; 2021 May; 5(5):CD011220. PubMed ID: 34037241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
    Huo X; Li J; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
    BMC Cancer; 2021 Jan; 21(1):78. PubMed ID: 33468087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials.
    Natori A; Ethier JL; Amir E; Cescon DW
    Eur J Cancer; 2017 May; 77():40-47. PubMed ID: 28355581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis.
    Li Y; Zhou Y; Mao F; Lin Y; Zhang X; Shen S; Sun Q
    Breast Cancer Res Treat; 2020 Feb; 179(3):533-542. PubMed ID: 31865475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Value of Capecitabine-Based Combination Adjuvant Chemotherapy in Early Breast Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Chen G; Guo Z; Liu M; Yao G; Dong J; Guo J; Ye C
    Oncol Res; 2017 Nov; 25(9):1567-1578. PubMed ID: 28337954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of platinum-based chemotherapy on the prognosis of early triple-negative breast cancer: a systematic review and meta-analysis.
    Zhao F; Shen G; Dong Q; Xin Y; Huo X; Wang M; Liu Z; Zhao Y; Ren D; Xie Q; Liu Z; Li Z; Gao L; Du F; Zhao J
    Clin Exp Med; 2023 Oct; 23(6):2025-2040. PubMed ID: 36422737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard chemotherapy: a new era? A meta-analysis of randomized controlled trials.
    Ye F; Bian L; Wen J; Yu P; Li N; Xie X; Wang X
    BMC Cancer; 2022 Mar; 22(1):261. PubMed ID: 35279130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moment of truth-adding carboplatin to neoadjuvant/adjuvant chemotherapy in triple negative breast cancer improves overall survival: An individual participant data and trial-level Meta-analysis.
    Pathak N; Sharma A; Elavarasi A; Sankar J; Deo SVS; Sharma DN; Mathur S; Kumar S; Prasad CP; Kumar A; Batra A
    Breast; 2022 Aug; 64():7-18. PubMed ID: 35462344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capecitabine in Combination with Standard (Neo)Adjuvant Regimens in Early Breast Cancer: Survival Outcome from a Meta-Analysis of Randomized Controlled Trials.
    Zhang ZC; Xu QN; Lin SL; Li XY
    PLoS One; 2016; 11(10):e0164663. PubMed ID: 27741288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First efficacy results of capecitabine with anthracycline- and taxane-based adjuvant therapy in high-risk early breast cancer: a meta-analysis.
    Jiang Y; Yin W; Zhou L; Yan T; Zhou Q; Du Y; Shen Z; Shao Z; Lu J
    PLoS One; 2012; 7(3):e32474. PubMed ID: 22396769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study.
    Taşçı EŞ; Kutlu Y; Ölmez ÖF; Mutlu AU; Gündoğdu Y; Seyyar M; Şahin E; Çabuk D; Majidova N; Uğurlu İ; Demirci A; Aydın D; Çavdar E; Bayram S; Yıldırım N; Karataş F; Eryılmaz MK; Çağlayan D; Menekşe S; Kut E; Arak H; Keser M; Sunar V; Perkin P; Şakalar T; Oyan B; Sönmez Ö; Özer L; Yıldız İ
    Expert Opin Pharmacother; 2024 Mar; 25(4):477-484. PubMed ID: 38568074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01).
    de Groot S; Pijl H; Charehbili A; van de Ven S; Smit VTHBM; Meershoek-Klein Kranenbarg E; Heijns JB; van Warmerdam LJC; Kessels LW; Dercksen MW; Pepels MJAE; van Laarhoven HWM; Vriens BEPJ; Putter H; Fiocco M; Liefers GJ; van der Hoeven JJM; Nortier JWR; Kroep JR;
    Breast Cancer Res; 2019 Aug; 21(1):97. PubMed ID: 31455425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platinum chemotherapy for early triple-negative breast cancer.
    Mason SR; Willson ML; Egger SJ; Beith J; Dear RF; Goodwin A
    Breast; 2024 Jun; 75():103712. PubMed ID: 38492276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01).
    Lluch A; Barrios CH; Torrecillas L; Ruiz-Borrego M; Bines J; Segalla J; Guerrero-Zotano Á; García-Sáenz JA; Torres R; de la Haba J; García-Martínez E; Gómez HL; Llombart A; Bofill JS; Baena-Cañada JM; Barnadas A; Calvo L; Pérez-Michel L; Ramos M; Fernández I; Rodríguez-Lescure Á; Cárdenas J; Vinholes J; Martínez de Dueñas E; Godes MJ; Seguí MA; Antón A; López-Álvarez P; Moncayo J; Amorim G; Villar E; Reyes S; Sampaio C; Cardemil B; Escudero MJ; Bezares S; Carrasco E; Martín M; ; ;
    J Clin Oncol; 2020 Jan; 38(3):203-213. PubMed ID: 31804894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer-A Meta-Analysis.
    Zhang Z; Ma K; Li J; Guan Y; Yang C; Yan A; Zhu H
    Front Pharmacol; 2021; 12():771839. PubMed ID: 34867401
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial.
    Wang X; Wang SS; Huang H; Cai L; Zhao L; Peng RJ; Lin Y; Tang J; Zeng J; Zhang LH; Ke YL; Wang XM; Liu XM; Chen QJ; Zhang AQ; Xu F; Bi XW; Huang JJ; Li JB; Pang DM; Xue C; Shi YX; He ZY; Lin HX; An X; Xia W; Cao Y; Guo Y; Su YH; Hua X; Wang XY; Hong RX; Jiang KK; Song CG; Huang ZZ; Shi W; Zhong YY; Yuan ZY;
    JAMA; 2021 Jan; 325(1):50-58. PubMed ID: 33300950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
    Radovich M; Jiang G; Hancock BA; Chitambar C; Nanda R; Falkson C; Lynce FC; Gallagher C; Isaacs C; Blaya M; Paplomata E; Walling R; Daily K; Mahtani R; Thompson MA; Graham R; Cooper ME; Pavlick DC; Albacker LA; Gregg J; Solzak JP; Chen YH; Bales CL; Cantor E; Shen F; Storniolo AMV; Badve S; Ballinger TJ; Chang CL; Zhong Y; Savran C; Miller KD; Schneider BP
    JAMA Oncol; 2020 Sep; 6(9):1410-1415. PubMed ID: 32644110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
    Villegas SL; Nekljudova V; Pfarr N; Engel J; Untch M; Schrodi S; Holms F; Ulmer HU; Fasching PA; Weber KE; Albig C; Heinrichs C; Marmé F; Hartmann A; Hanusch C; Schmitt WD; Huober J; Lederer B; van Mackelenbergh M; Tesch H; Jackisch C; Rezai M; Sinn P; Sinn BV; Hackmann J; Kiechle M; Schneeweiss A; Weichert W; Denkert C; Loibl S
    Eur J Cancer; 2021 May; 148():159-170. PubMed ID: 33743484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36,480 cases.
    Xia LY; Hu QL; Zhang J; Xu WY; Li XS
    World J Surg Oncol; 2020 Jun; 18(1):129. PubMed ID: 32539858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.